Gelomics is revolutionizing drug development by enabling the growth of human tissue models in vitro. This provides an ethical, cost-effective, and predictive alternative to animal testing.
The Gelomics leadership team is composed of experienced professionals. They are dedicated to advancing the company’s vision of transforming drug discovery through innovative 3D cell culture solutions.
An award-winning researcher with 50+ publications and 2,800+ citations. Since 2017, Dr. Meinert has secured $12M+ in funding, led 17 global product developments, and expanded Gelomics to 23 markets. His work is widely recognized in top-tier scientific journals and biotech innovation.
Peter holds a PhD in the development of novel biomaterials for tissue engineering - the technology and materials behind Gelomics' first products. A chartered chemical engineer and graduate of the Australian Institute of Company Directors, he brings extensive experience in capital raising, technology development, commercialisation and team growth.
Anjali is a recognised leader in biomedical innovation, medical robotics, and translational health technologies, with over a decade of experience. She has driven the creation of biomedical centres of excellence and secured over AUD $19M for collaborative research. Her expertise spans biotech research, regulatory strategy, and cross-sector partnerships. Her work has been featured on TEDx, Sky News, The Guardian, The Economic Times, and global scientific forums.
Emma is a Biomedical Science graduate with a strong background in biotechnology and commercial strategy. With experience spanning scientific research, business development, and product management, she has worked globally with pharmaceutical companies to drive efficiency. Now a Sales and Applications Specialist at Gelomics, Emma specializes in advancing 3D cell culture technologies for research and drug discovery.
Leading strategic initiatives to drive the commercialization of cutting-edge 3D cell culture technologies. With over 10 years of experience in marketing and expertise in go-to-market strategy and biotech innovation, she bridges science and business to accelerate adoption. As a UQ MBA candidate, Hayley brings a strong analytical and leadership approach to positioning Gelomics at the forefront of the industry.
Dr. Pawel Mieszczanek leads engineering at Gelomics, developing innovative lab devices and software solutions. With a PhD in engineering and extensive experience in the medical device and biotech industries, he brings expertise in product development, mechatronics, and AI/ML. He is passionate about driving product development and leading high-performing teams.
These distinguished leaders in their fields bring a wealth of knowledge and expertise to Gelomics, therefore driving our mission of revolutionizing drug development with cutting-edge 3D cell culture technology.
Professor Stevens is the John Black Professor of Bionanoscience at Oxford University, serving in the Institute for Biomedical Engineering and the Department of Physiology, Anatomy, and Genetics. Additionally, she is Deputy Director of the Kavli Institute for Nanoscience Discovery. Holding a PhD from the University of Nottingham and postdoctoral experience at MIT, she led research at Imperial College London and remains part-time faculty. Additionally, she is a Biomaterials Professor at Karolinska Institutet. Recognized for her work in biosensing, regenerative medicine, and therapeutics, she has published over 400 papers and holds numerous patents, including four spin-out companies. Furthermore, Prof. Stevens has received over 40 awards, including the Novo Nordisk Award (2023), and is a Fellow of several prestigious institutions, such as the Royal Society.
Professor Hutmacher, co-founder of Gelomics, and current Director of the Max Planck Queensland Centre for the Materials Science of Extracellular Matrices, is a globally recognised leader in tissue engineering and regenerative medicine. With decades of industrial and academic excellence, Professor Hutmacher has pioneered numerous biomedical innovations. Moreover, he has authored over 500 journal articles, edited 14 books, and holds an h-index of 133 with over 75,000 citations. As a result, his role at Gelomics will leverage his expertise in translating research into commercial and clinical applications, driving biomaterials technology forward.
Professor Klein, co-founder of Gelomics, is a distinguished figure in the field of biomedical engineering at the Queensland University of Technology (QUT). As leader of the Cartilage Regeneration Laboratory, he develops regenerative therapies for cartilage defects. His senior QUT roles and 10,000+ citations will be invaluable as Gelomics pioneers innovative, non-animal drug development methodologies.
Professor Gail Risbridger, a Distinguished Professor at Monash University, is an internationally acclaimed leader in men’s health, urology, and translational oncology, renowned for directing globally recognised, multidisciplinary research programs that accelerate drug development and clinical translation. Her groundbreaking contributions have significantly influenced policy and clinical practice both in Australia and abroad, notably shaping the Australian National Men's Health Policy. Her work has earned numerous prestigious accolades, including the Fulbright Senior Scholar Award (2001), four NH&MRC Research Fellowships (1996–2021), the Endocrine Society of Australia Lifetime Achievement and Senior Plenary Awards (2008 & 2012), Fellowship of the Society of Reproductive Biology (2015), Fellowship of the Australian Academy of Health and Medical Science (2019), and appointment as a Member of the Order of Australia (AM) in the 2023 Australia Day Honours.
+61 1800 865 060
Send us an email here
60 Musk Avenue
Kelvin Grove, QLD 4059
Australia
ABN 14 624 623 623
